Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Relating to Recothrom Thrombin, topical recombinant
Subscribe to our email newsletter
ZymoGenetics has reported a restructuring of the US co-promotion and ex-US license and collaboration agreements with Bayer Schering Pharma and Bayer HealthCare relating to Recothrom Thrombin, topical (Recombinant).
Reportedly, effective January 1, 2010, ZymoGenetics regains full promotion rights in the US and all ex-US rights except in Canada, where Bayer will market and sell the product.
As per the terms of the revised agreements, active co-promotion by Bayer in the US will end on December 31, 2009; Bayer will receive its normal sales commission through that date. Beginning in 2010, Bayer will receive a reduced sunset period commission through December 31, 2011, which was previously capped at $25m per year and now will be subject to an aggregate maximum of $12m.
ZymoGenetics will no longer be required to pay Bayer US sales bonus payments totaling $20m, which were anticipated to have been payable in 2010 and 2011 or upon termination of the co-promotion agreement.
Furthermore, outside the US, ZymoGenetics will regain all rights to Recothrom except for Canada. In Canada, Bayer will sell the product and pay royalties on net sales to ZymoGenetics. Bayer will no longer be required to pay ZymoGenetics up to $16m in milestone payments for ex-US regulatory approvals. ZymoGenetics will assume responsibility for all active regulatory files in countries besides Canada.
Douglas Williams, CEO of ZymoGenetics, said: “The amended agreements with Bayer should benefit ZymoGenetics in a number of ways. The US marketing and sales operation should achieve greater efficiency with one sales organisation. We plan to increase the size of our field force to compensate for Bayer’s exit. However, despite this increase, we expect the change to lower our selling costs and improve our bottom line, while enabling us to continue to gain market share.”
“We continue to believe there is substantial potential value to be gained from the commercialization of Recothrom outside the US. We intend to seek new licensees to pursue the development of these markets.”